Quigley Pharma Compound QR-443 Effective In Preventing Cachexia (Muscle Wasting)

Quigley Pharma, a
wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY),
announced today that it has obtained positive results for its QR-443
compound for the treatment of Cachexia, a debilitating and life threatening
muscle wasting condition. The results of an animal study found a 75%
efficacy rate in the treatment of mice with this condition.


The results of the study clearly indicated that 75% of the tested mice
injected with 5 mg of QR-433 were protected from Cachexia and did not
exhibit any significant weight loss compared to untreated control animals
which exhibited a 15-25 percent weight loss at the end of the experiment.


Cachexia, an extremely debilitating and life threatening condition, is
a loss of weight, muscle wasting, fatigue, weakness and decrease of
appetite which occurs in wasting diseases such as cancer, AIDs, chronic
renal failure, advanced aging and rheumatoid arthritis. Increases in the
blood levels of the cytokines IL-6, TNF-a and INF-y have been thought to
play a major role in Cachexia.


QR-443 is an all natural broad spectrum anti-inflammatory compound that
is being concurrently studied as a drug for Rheumatoid Arthritis (under the
designation QR-440) in humans and dogs. QR-443 has been shown in previous
pre-clinical studies to inhibit the production of TNFa and IFN gamma, and
reducing other inflammatory cytokines associated with Cachexia. This is a
significant and extremely positive development as systemic inflammation has
also been associated with poor prognosis in patients with cancer.


The QR-443 study was undertaken by Professor Yacov Ron of the
Department of Molecular Genetics and Microbiology at the Robert Wood
Johnson Medical School, University of Medicine and Dentistry of New Jersey.


Dr. Richard Rosenbloom, Chief Operating Officer, Quigley Pharma,
stated, "The significant findings of the study are sufficient to continue
to the next stage of the drug development process. We plan to investigate
the possibility of Fast Track Status with the FDA. Alternatively, due to
the importance of these findings, the Company may consider launching this
product as a neutraceutical."


The Quigley Corporation makes no representation that the US Food and
Drug Administration or any other regulatory agency will grant an
Investigational New Drug ("IND") or take any other action to allow its
formulations to be studied or/and for any Investigational New Drug to be
marketed. Furthermore, no claim is made that potential medicine discussed
herein is safe, effective, or approved by the Food and Drug Administration.
Additionally, data that demonstrates activity or effectiveness in animals
or in vitro tests do not necessarily mean the formula test compound,
referenced herein will be effective in humans. Safety and effectiveness in
humans will have to be demonstrated by means of adequate and well
controlled clinical studies before the clinical significance of the formula
test compound is known. Readers should carefully review the risk factors
described in filings the Company files from time to time with the
Securities and Exchange Commission.















About The Quigley Corporation


The Quigley Corporation (Nasdaq: QGLY, QuigleyPharma) is a
diversified natural health medical science company. Its Cold Remedy segment
is a leading marketer and manufacturer of the COLD-EEZE(R) family of
lozenges, gums and sugar free tablets clinically proven to cut the common
cold nearly in half. COLD-EEZE customers include leading national
wholesalers and distributors, as well as independent and chain food, drug
and mass merchandise stores and pharmacies. The Quigley Corporation has
several wholly owned subsidiaries. Darius International markets health and
wellness products through its wholly owned subsidiary, InnerLight Inc.
Quigley Manufacturing Inc. consists of two FDA approved facilities to
manufacture COLD-EEZE(R) lozenges as well as fulfill other contract
manufacturing opportunities. Quigley Pharma Inc.


(QuigleyPharma) conducts research in order to develop and
commercialize a pipeline of patented botanical and naturally derived
prescription drugs.


Forward-Looking Statements


Certain statements in this press release are "forward-looking
statements" within the meaning of the Private Securities Litigation Reform
Act of 1995 and involve known and unknown risk, uncertainties and other
factors that may cause the Company's actual performance or achievements to
be materially different from the results, performance or achievements
expressed or implied by the forward-looking statement. Factors that impact
such forward-looking statements include, among others, changes in worldwide
general economic conditions, changes in interest rates, government
regulations, and worldwide competition.


QuigleyPharma